CXCL5 and nasopharyngeal carcinoma: Zhang et al. [30] showed that serum CXCL5 levels could serve as a prognostic biomarker in nasopharyngeal carcinoma, while Lim et al. [31] indicated that serum CXCL5 levels could serve as potential biomarkers to predict the distant metastasis of primary gastric cancer, and Kawamura et al. [32] identified serum CXCL5 levels as a potential prognostic biomarker for colorectal cancer.